Boston Scientific Corp. reported positive data for two key atrial fibrillation therapies at AF Symposium 2025 on January 17.

The talks around drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices ...

The sedate uptake of pulsed field ablation (PFA) in Europe failed to presage the enthusiasm that drove the technology’s extraordinarily rapid adoption in the U.S. in 2024. Used to treat atrial ...

Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's ...

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the ...

According to the latest study from BCC Research, the demand for Conventional and Alternative Pain Treatment Markets is ...

1Mass General Cancer Center, Boston, Massachusetts. 2Harvard Medical School, Boston, Massachusetts. *Corresponding Author: Gregory M. Cote, Mass General Cancer Center ...

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable ...

AbbVie (ABBV) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...

1Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts. 2Center for Cancer Research, Center for Regenerative Medicine, Massachusetts General, Boston, ...

Drug giant AbbVie has a significant option agreement ... Learn More » Aldeyra Therapeutics, Inc. is headquartered just outside of Boston in Lexington, MA. The company is focused on developing ...